Department of Internal Medicine N 2, Kursk State Medical University, 14 Pirogova St., Kursk 305035, Russian Federation.
Department of Pharmacology, Kursk State Medical University, 3 Karl Marx St., Kursk 305041, Russian Federation.
Pharmacogenomics. 2022 Jan;23(1):15-34. doi: 10.2217/pgs-2021-0097. Epub 2021 Dec 15.
Polymorphisms at , , , , and are attractive targets for assessment of their impact on lipid-lowering therapy with rosuvastatin. The present study investigated whether polymorphisms at these genes are associated with the risk of coronary artery disease (CAD) development, and reduction of atherogenic lipids and carotid intima-media thickness (CIMT) in CAD patients, taking rosuvastatin. 190 CAD patients and 1697 subjects were enrolled in pharmacogenetic and genetic association study, respectively. SNP genotyping was done using the MassARRAY-4 system. rs6924995, rs3757354, rs445925, rs6511720, rs7412, rs2199936, rs1481012 variants were significantly associated with CAD susceptibility (p = 0.016, 0.0003, <0.0001, <0.0001, 0.013, 0.016, 0.0035, respectively), as well as with CIMT regression (except variants; p = 0.05, 0.039, 0.039, 0.016, 0.0065), and changes in plasma lipids during rosuvastatin therapy. The studied polymorphisms possess pleiotropic effects on plasma lipids and CIMT, CAD susceptibility, and determine lipid-lowering response to rosuvastatin.
、、、、和 上的多态性是评估瑞舒伐他汀降脂治疗影响的有吸引力的靶点。本研究旨在探讨这些基因的多态性是否与冠心病（CAD）患者服用瑞舒伐他汀后发生 CAD 发展、致动脉粥样硬化脂质和颈动脉内膜中层厚度（CIMT）降低的风险相关。共纳入 190 例 CAD 患者和 1697 例对照进行遗传关联研究。采用 MassARRAY-4 系统进行 SNP 基因分型。rs6924995、rs3757354、rs445925、rs6511720、rs7412、rs2199936、rs1481012 变体与 CAD 易感性显著相关（p=0.016、0.0003、<0.0001、<0.0001、0.013、0.016、0.0035），与 CIMT 回归也显著相关（除 rs445925 变体；p=0.05、0.039、0.039、0.016、0.0065），以及在瑞舒伐他汀治疗期间对血浆脂质的影响。所研究的多态性对血浆脂质和 CIMT、CAD 易感性具有多效性影响，并决定了瑞舒伐他汀的降脂反应。
